Catalog No.
DHF19801
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Claudin-18, CLDN18
Concentration
3.3 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P56856
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Claudin 18.2, GC-182, IMAB-362, IMAB362, Claudiximab, CAS: 1496553-00-4
Clone ID
Zolbetuximab
1，Characterization of zolbetuximab in pancreatic cancer models，OncoImmunology，Volume 8, 2019 - Issue 1 ， https://doi.org/10.1080/2162402X.2018.1523096
2，Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer， J Hematol Oncol. 2017 May 12;10(1):105. doi: 10.1186/s13045-017-0473-4.
3，Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma,https://doi.org/10.1093/jjco/hyz068
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study, PMID: 31240302
Characterization of zolbetuximab in pancreatic cancer models, PMID: 30546962
A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer, PMID: 29936063
Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer, PMID: 32410803
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer, PMID: 28494772
Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma, PMID: 31087075
Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms, PMID: 23900716
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma, PMID: 33610734
Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma, PMID: 33755863
PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation, PMID: 32499871
Claudin 18.2-a FAST-moving target in gastric cancer?, PMID: 33677015
Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy, PMID: 33590909
Antibody Improves Survival in Gastric Cancer, PMID: 27297550
Peptide microarrays enable rapid mimotope optimization for pharmacokinetic analysis of the novel therapeutic antibody IMAB362, PMID: 24497417
For research use only. Not for human or drug use.
